Quince Therapeutics, Inc.
QNCX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001662774
No open-market purchases or sales by Quince Therapeutics, Inc. insiders were filed in the last 90 days; 26 institutions reported holding it in 13F filings for Q2 2026, worth $4.74M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −20 vs. previous quarter
- 26
- 13F valueReported value at the end of Q2 2026
- $4.74M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding QNCX, Q2 2026
No superinvestor reported holding QNCX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Quince Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 29, 2025 (view filing) | Dec 26 | 3 days | Benatti LucaDirector | SSale | −50.0K | $3.47 | −$173.5K | −56.1%39.2K after | |
| Sep 3, 2024 (view filing) | Aug 29-30 | 5 days | Thye DirkCEO AND CHIEF MEDICAL OFFICER | PPurchase | +154.5K | $0.695 | +$107.4K | +22.4%843.9K after | 2 lots |
| Aug 22, 2024 (view filing) | Aug 20 | 2 days | Ryan Charles S.PRESIDENT | PPurchase | +48.4K | $0.65 | +$31.5K | +65.3%122.5K after | |
| Aug 21, 2024 (view filing) | Aug 19-21 | 2 days | Hannah BrendanCHIEF BUSINESS OFFICER AND COO | PPurchase | +38.9K | $0.6209 | +$24.2K | +15.1%296.5K after | 6 lots |
| Dec 14, 2023 (view filing) | Dec 12-14 | 2 days | Lamond DavidDirector | PPurchase | +45.6K | $1.02 | +$46.5K | +2.0%2.35M after | 3 lots |
| Dec 14, 2023 (view filing) | Dec 12 | 2 days | Lamond DavidDirector | PPurchase | +22.3K | $1.02 | +$22.8K | +1.0%2.30M after | |
| Dec 7, 2023 (view filing) | Dec 5-7 | 2 days | Lamond DavidDirector | PPurchase | +57.4K | $1.01 | +$58.1K | +2.6%2.28M after | 3 lots |
| Dec 1, 2023 (view filing) | Nov 29-Dec 1 | 2 days | Lamond DavidDirector | PPurchase | +43.1K | $0.94 | +$40.5K | +2.0%2.22M after | 3 lots |
| Aug 31, 2023 (view filing) | Aug 30-31 | 1 day | Lamond DavidDirector | PPurchase | +82.1K | $1.32 | +$107.9K | +3.9%2.18M after | 2 lots |
| Aug 17, 2023 (view filing) | Aug 15-17 | 2 days | Lamond DavidDirector | PPurchase | +250.0K | $1.30 | +$325.7K | +13.5%2.10M after | 3 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Quince Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ikarian Capital, LLC | 72,251 | $1.31M | 0.22% | +72,251 | New |
| Millennium Management LLC | 70,779 | $1.29M | 0.00% | −2,432,938−97.2% | Reduced |
| Squadron Capital Management LLC | 40,375 | $734.4K | 0.25% | +40,375 | New |
| Shay Capital LLC | 17,468 | $329.3K | 0.04% | −1,755,441−99.0% | Reduced |
| Boothbay Fund Management, LLC | 13,911 | $253.0K | 0.00% | +13,911 | New |
| Jane Street Group, LLC | 12,642 | $230.0K | 0.00% | +12,642 | New |
| Vanguard Capital Management LLC | 12,044 | $219.1K | 0.00% | −449,433−97.4% | Reduced |
| Cormorant Asset Management, LP | 5,498 | $100.0K | 0.01% | +5,498 | New |
| UBS Group AG | 4,730 | $86.0K | 0.00% | +4,174+750.7% | Added |
| Morgan Stanley | 4,084 | $74.3K | 0.00% | +3,250+389.7% | Added |